<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964597</url>
  </required_header>
  <id_info>
    <org_study_id>EBA_2019_9</org_study_id>
    <nct_id>NCT03964597</nct_id>
  </id_info>
  <brief_title>Objective Measurements of Lens Opacification After Intravitreal Injections</brief_title>
  <acronym>MOC-IVT</acronym>
  <official_title>Objective Measurements of Lens Opacification After Intravitreal Injections (MOC-IVT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main hypothesis is the opacification of the lens would be increase by the IVT.

      The opacification of the lens can be objectived by :

        -  the objective scatter index (OSI) on the OQAS device

        -  the average lens density (ALD) on the IOLMaster device.

      Eligible patients will be followed at least 12 months after in intravitreal injection and the
      opacification of their lens is regularly controlled with OSI and ALD.

      The objective is to study the dynamics of lens opacification in IVT-treated eyes evaluated by
      OSI for at least 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study abandoned before any submission (foreseeable organizational difficulties)
  </why_stopped>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Value of the OSI (Objective Scatter Index) in one year of follow-up after IVT</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Lens Opacification</condition>
  <condition>Intravitreal Injections (IVT)</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Measurement of lens opacification</intervention_name>
    <description>Measurement of OSI and ALD at inclusion and during post-IVT follow-up visits to M3, M6, and M12, +/- M18, +/- M24 and +/- M30.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an indication for intravitreal injection (IVT) for medical condition.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  An indication of an intravenous injection of a dexamethasone 700 μg (Ozurdex®) or
             anti-VEGF for at least one of the two eyes for macular edema or neovessels linked to
             DMLA, retinal venous occlusion, diabetic macular edema or posterior uveitis

          -  Phake patient, at least of the injected eye

        Exclusion criteria:

        - Pseudophakia of the injected eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>objective scatter index (OSI)</keyword>
  <keyword>average lens density (ALD)</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

